 Hormonal Balance
Astragaloside IV
|
Cardiovascular Health
Astragaloside IV from Astragalus membranaceus showed cardioprotection during myocardial ischemia in vivo and in vitro.
Zhang, W. 2006
Astragaloside (AS) and Astragalus injections had some protective effects on myocardial injury of viral myocarditis in mice.
Lu, S. 1999
Astragaloside IV reduces inflammation in endothelial cells (cells in arterial walls).
Zhang 2003
Astragaloside IV inhibited vessel contraction through blocking calcium influx and intracellular calcium release.
Zhang, C. 2007
Astragaloside IV relieved symptoms of chest distress and dispnea in 15 patients after two weeks of treatment.
Za Zhi
Astragaloside IV showed to have a 'marked' nueroprotective effect of rats intentionally given an stroke ('ischemic brain injury').
Luo, Y. 2004
Astragaloside extracts improved the immune function of patients with congestive heart failure.
Liu, Z. 2003
Bioavailability
The absolute bioavailability of astragaloside IV in rats after an oral dose was 2.2%.
Gu, Y. 2004
Fifty percent of Astragaloside IV administered via i.v. to rats was metabolized in vivo. The bioavailability was found to be 3.66%.
Du, Y. 2005
Astragaloside IV may have difficulty crossing the blood-brain barrier. The pharmokinetics of Astragaloside IV are 'favorable'.
Zhang 2006
The absolute bioavailability of AGS-IV after p.o. [oral] administration in Beagle dog was found to be 7.4%. There was no significant species difference regarding the pharmacokinetics of AGS-IV between the rat and the Beagle dog.
Zhang 2007
Chitosan and sodium deoxycholate can be used as absorption enhancers for Astragaloside IV.
Huang CR 2006
Nueroprotective
Astragaloside IV was investigated for its capacity to protect dopaminergic neurons in experimental Parkinson's disease. It was found that AS-IV pretreatment significantly and dose-dependently attenuated 6-OHDA-induced loss of dopaminergic neurons.
Chan WS 2009
Know of a good study for Astragaloside IV but don't see it here? Add your own.
|